What Is

Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What’s Missed on Intuitive Surgical, Inc. (ISRG)’s Big Miss

Investors got little warning on Intuitive Surgical, Inc. (NASDAQ:ISRG)‘s big second quarter miss. The first most heard about it might have been the company’s own press release – the company doesn’t officially report until next week.

In practical terms the miss isn’t much – revenue of $575 million against an expected $630 million, and net income of $160 million instead of $177.7 million. But the stock, which was previously priced to perfection, fell out of bed anyway, dropping over 17% and shedding $2.87 billion in market cap overnight.

Intuitive Surgical, Inc. (NASDAQ:ISRG)

What’s going on?

Sean Williams blames Obamacare, saying uncertainty over future payments is causing hospitals to stop buying. Dan Carroll suspects a series of FDA questions about the safety and efficacy of Intuitive’s DaVinci system may be to blame, while Karl Thiel wants you to see an exclusive report on the matter.

Before all this, Intuitive Surgical, Inc. (NASDAQ:ISRG) was a big favorite here. Brian Stoffel had it on his ideal portfolio. The Fool was recommending it explicitly, and even its purchases were moving markets.

The nature of a tech market

Having covered the medical device market since 2006, here is my take.

First, DaVinci robots are a miracle. They increase a surgeon’s productivity, and they reduce mistakes when compared with doing operations by hand. Over time, they increase a surgery center’s profitability and reduce its liability.

But this is a technology market. Just because you’ve got something that’s cool doesn’t mean you’ll always be able to sell it at whatever price you set. Eventually the market moves through its demand curve, which means prices and margins must go down. As Jim Cramer noted last month, the price of Intuitive shares were overextended, on a technical basis.

Also, just because Intuitive Surgical has lots of patent protection on how DaVinci works, this doesn’t mean no one else can make a robotic surgeon. As Keith Speights wrote on July 2, there is now competition in this market.

The competition is minor

Fortunately for Intuitive, and its shareholders while there are other companies in this market, they’re generally small, specialized, and far more troubled than Intuitive is.

MAKO Surgical Corp. (NASDAQ:MAKO) has a robot that focuses on orthopedic procedures, which was used over 10,000 times last year. The company is not yet profitable, although sales are up 20% year-over-year, but it’s debt-free, it had a great fourth quarter of 2012, which generated cash, and its RIO system could, over time, become directly competitive with Intuitive in other areas of surgery.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.